Immunic Inc Market Cap ($103.52 Million)
Market Cap & Net Worth: Immunic Inc (IMUX)
Immunic Inc market cap. Immunic Inc (NASDAQ:IMUX) has a market capitalization of $103.52 Million ($103.52 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18869 globally and #4379 in its home market, demonstrating a 4.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunic Inc's stock price $7.60 by its total outstanding shares 13621526 (13.62 Million). Also see IMUX cash flow metrics for how efficiently the company converts equity into cash flow.
Immunic Inc Market Cap History (2015–2026)
Immunic Inc market cap history from 2015 to 2026. Data shows change from $6.28 Billion to $103.52 Million (-27.12% CAGR). Check IMUX live share price for real-time trading data and today's change.
Index Memberships
Immunic Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #521 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1811 of 3165 |
Weight: Immunic Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunic Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunic Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMUX net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
395024.25x
Immunic Inc's market cap is 395024.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.37 Billion | $6.00K | -$40.97 Million | 395024.25x | N/A |
Competitor Companies of IMUX by Market Capitalization
Companies near Immunic Inc in the global market cap rankings as of November 4, 2026. Also see IMUX total asset value for a full breakdown of the balance sheet.
Key companies related to Immunic Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Immunic Inc (2015–2026)
Market capitalization of Immunic Inc from 2015 to today. Between 2015 and today, Immunic Inc's market cap moved from $6.28 Billion to $ 103.52 Million, with a yearly change of -27.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $103.52 Million | +1324.02% |
| 2025 | $7.27 Million | -46.63% |
| 2024 | $13.62 Million | -33.33% |
| 2023 | $20.43 Million | +7.14% |
| 2022 | $19.07 Million | -85.37% |
| 2021 | $130.36 Million | -37.41% |
| 2020 | $208.27 Million | +57.63% |
| 2019 | $132.13 Million | +30.38% |
| 2018 | $101.34 Million | -96.87% |
| 2017 | $3.24 Billion | +36.78% |
| 2016 | $2.37 Billion | -62.24% |
| 2015 | $6.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Immunic Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.52 Million USD |
| MoneyControl | $103.52 Million USD |
| MarketWatch | $103.52 Million USD |
| marketcap.company | $103.52 Million USD |
| Reuters | $103.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more